Valenzuela-Siqueiros ÁM, Sterling-Pamplona M, Badial-López JP, Fandiño-Izundegui J, Morales-Cadena GM

Language: Spanish
References: 13
Page: 16-22
PDF size: 209.08 Kb.

ABSTRACT

Objective: To describe the proportion of symptoms and comorbidities in patients infected with SARS-CoV-2 at Hospital Español in Mexico City.
Material y Método: A cross-sectional/descriptive study, done at Hospital Español in Mexico City with SARS-CoV-2 positive patient medical files from March to July 2020.
Results: In the studied period, 239 patients were found, 84 (35%) female and 155 (65%) males. The most frequent age ranges were 40-69 years, 162 (62%). Patients with outpatient care were 85 (35%) showing a higher proportion of the following symptoms: asthenia and adynamia (67%), myalgia and arthralgia (57.6%), fever (52.9%), headache (50.5%) and cough (48.2%). Hospitalized patients were 154 (64.4%) and showed a higher frequency of the following symptoms: asthenia and adynamia (66.8%), dyspnea (64.9%), fever (61.6%), myalgia and arthralgia (59%) and cough (57.1%). Those 34 patients who died presented: asthenia and adynamia (64%), dyspnea (61%), fever (61%) and cough (50%).
Conclusions: There was a higher percentage of males and patients between 40 and 69 years old, a higher proportion of patients required in-hospital care. Symptoms in more severe patients were asthenia, adynamia, dyspnea, fever and cough, symptoms than should alert us about possible complications.

REFERENCES

1. Lohse A, Klopfenstein T, Balblanc JC, Royer PY, et al. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Microbes Infect 2020; 22 (9): 500-503. doi:10.1016/j.micinf.2020.06.005.

2. Urra JM, Cabrera CM, Porras L, Ródenas I. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol 2020; 217: 108486. doi:10.1016/j. clim.2020.108486.

3. Aragón-Nogales R, Vargas-Almanza I, Miranda-Novales MG. COVID-19 por SARS-CoV-2: la nueva emergencia de salud. Rev Mex Pediatr 2019; 86 (6): 213-218.

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585.

5. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433. Available in: https://doi. org/10.1016/j. jaut.2020.102433.

6. Wayne Dimech B. Part 1: key facts in COVID-19 test. Westgard Web April 2020.

7. Domínguez JS, Domínguez NS, Reyes NM. Cómo estimar la letalidad del COVID-19. Rev Mex Patol Clin Med Lab 2020; 67 (1): 4-8. doi: 10.35366/93845.

8. Grasselli G, Greco M, Zanella A, Albano, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy Italy. JAMA Intern Med 2020; 180 (10): 1345-1355. doi:10.1001/jamainternmed. 2020.3539.

9. Li T, Lu L, Zhang W, et al. Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. Arco Gerontol Geriatr 2020; 91: 104185. doi:10.1016/j. archger.2020.104185.

10. Sattar N, McInnes IB, McMurray JJV. Obesity is a risk factor for severe COVID-19 infection: Multiple potential mechanisms. Circulation 2020; 142 (1): 4-6. doi: 10.1161/ CIRCULATIONAHA.120.047659.

11. Duarte R, Furtado I, Sousa L, Carvalho CFA. The 2019 novel coronavirus (2019-nCoV): Novel virus, old challenges. Acta Méd Port 2020; 33 (13). doi: 10.20344/amp.13547.

12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020. https://doi.org/10.1016/S0140-6736(20)30211-7.

13. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 2020; 28 (7): 1195-1199. doi:10.1002/ oby.22831.